Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation.
Le
Quan
Q
Shenoy
Aarthi
A
Koklanaris
Eleftheria
E
Childs
Richard
R
John Barrett
A
A
Savani
Bipin N
BN
D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006509:Hepatitis B / Q000401:mortality* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006515:Hepatitis B virus; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous; D014611:Vaccination; D014775:Virus Activation / Q000187:drug effects
D019380:Anti-HIV Agents; D017325:Hepatitis B Vaccines; D019259:Lamivudine